Valuation: Epigenomics AG

Market Cap 798K 915K 752K 685K 1.28M 87.69M 1.28M 9M 3.47M 44.67M 3.44M 3.36M 144M P/E 2024
-0.29x
P/E 2025 -2.51x
Enterprise Value 11.77M 13.49M 11.08M 10.09M 18.92M 1.29B 18.94M 133M 51.15M 659M 50.69M 49.56M 2.12B EV / Sales 2024
-
EV / Sales 2025 490x
Free-Float
70.75%
Yield 2024 *
-
Yield 2025 -
Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal 55 01/02/2024
Director TitleAgeSince
Chairman 58 01/03/2023
Director/Board Member 55 01/06/2020
Director/Board Member 56 05/02/2024
Change 5-day change 1-year change 3-year change Capi.($)
-0.59%+10.04%+397.07%+102.38% 4.62B
-2.62%+12.43%+108.53%+437.84% 4.45B
+4.33%+0.75%+21.72%+83.72% 3.34B
+0.93%+3.74%+272.38%+601.03% 2.81B
+6.75%+15.41%-16.39%-19.04% 2.43B
-2.98%+10.96%+56.60% - 1.78B
+0.89%+6.73%+28.20%+62.00% 1.13B
+2.87%+7.26%+165.56%-28.59% 1.07B
+5.23%+1.37%-15.35%+65.52% 604M
Average +1.65%+7.58%+113.15%+163.11% 2.47B
Weighted average by Cap. +0.95%+8.64%+153.61%+216.27%

Financials

2024 2025
Net sales - 24K 27.53K 22.6K 20.59K 38.6K 2.64M 38.64K 271K 104K 1.34M 103K 101K 4.33M
Net income -3.35M -3.84M -3.16M -2.88M -5.39M -368M -5.4M -37.81M -14.57M -188M -14.44M -14.12M -605M -314K -360K -296K -269K -505K -34.5M -506K -3.54M -1.37M -17.58M -1.35M -1.32M -56.71M
Net Debt 10.46M 11.99M 9.85M 8.97M 16.81M 1.15B 16.83M 118M 45.45M 585M 45.04M 44.04M 1.89B 10.97M 12.58M 10.33M 9.41M 17.64M 1.21B 17.66M 124M 47.68M 614M 47.25M 46.2M 1.98B
Logo Epigenomics AG
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Employees
-
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!